J&J's pharma sales propped up by weak dollar
This article was originally published in Scrip
Executive Summary
The downturn inJohnson & Johnson's pharmaceutical sales has continued into the third quarter following persistent generic competition for its key products. For the third successive quarter the weakness of the dollar has allowed the company to post growth.